Moderna Shares Surge on Nasdaq 100 Return and Cancer Vaccine Data
Moderna shares surged 14.21% to reach a new 52-week high, driven by institutional re-entry into the Nasdaq 100 and clinical momentum in personalized cancer vaccines developed alongside Merck. This market ... Read More